More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback